BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer. (Q51628000)
Jump to navigation
Jump to search
scientific article published on 26 May 2015
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer. |
scientific article published on 26 May 2015 |
Statements
BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer. (English)
1 reference
Caicun Zhou
1 reference
Yi-Long Wu
1 reference
Gongyan Chen
1 reference
Xiaoqing Liu
1 reference
Yunzhong Zhu
1 reference
Shun Lu
1 reference
Jifeng Feng
1 reference
Jianxing He
1 reference
Baohui Han
1 reference
Jie Wang
1 reference
Guoliang Jiang
1 reference
Chunhong Hu
1 reference
Hao Zhang
1 reference
Gang Cheng
1 reference
Xiangqun Song
1 reference
You Lu
1 reference
Hongming Pan
1 reference
Wenjuan Zheng
1 reference
Anny-Yue Yin
1 reference
26 May 2015
1 reference
33
1 reference
19
1 reference
2197-2204
1 reference